Product Program year 2025 Source: CMS Open Payments

Alyglo

Drug Immunology

NDC 61476-104-05

Open in the dashboard

General payments

$64,132

722 payments

Research payments

$0

0 payments

Through program year 2025, $64,132 in general payments and $0 in research payments were reported against Alyglo (Immunology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

1 row
Year Kind Amount Payments
2025 General $64,132 722

Breakdown

Who paid General payments · program year 2025
  1. GC Biopharma USA, Inc. $64,021 721 payments
  2. GC Biopharma Corp. $111 1 payment
Top recipients General payments · program year 2025
  1. Raffi Tachdjian Allergy & Immunology · Santa Monica, CA $10,293 16% · 9 payments
  2. Bob Geng Allergy & Immunology · San Diego, CA $7,300 11% · 4 payments
  3. Antoine Azar Allergy & Immunology · Baltimore, MD $6,600 10% · 1 payment
  4. Daniel Suez Allergy & Immunology · Irving, TX $4,062 6% · 4 payments
  5. Richard Wasserman Urogynecology and Reconstructive Pelvic Surgery · Henderson, NV $3,500 5% · 1 payment

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Allergy & Immunology $34,511 54% · 221 practitioners
  2. Allergy & Immunology Internal Medicine $9,621 15% · 14 practitioners
  3. Allergy Allergy & Immunology $4,637 7% · 45 practitioners
  4. Urogynecology and Reconstructive Pelvic Surgery Obstetrics & Gynecology $3,500 6% · 1 practitioner
  5. Nurse Practitioner, Family Nurse Practitioner $2,126 3% · 22 practitioners

The top 5 of 25 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. California $20,123 31% · 20 recipients
  2. Texas $7,802 12% · 41 recipients
  3. Maryland $6,633 10% · 3 recipients
  4. Arizona $4,761 7% · 36 recipients
  5. Nevada $3,524 5% · 2 recipients

The top 5 of 36 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

722 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record